Traws Pharma (TRAW) grants CFO Parker Nolan 90,000 stock options
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Traws Pharma, Inc. reported that Chief Financial Officer Parker Charles Nolan received a grant of 90,000 stock options to purchase common stock. The options have an exercise price of $0.68 per share, vest 100% on the first anniversary of the July 9, 2026 grant date, and expire on July 9, 2036. The award was approved by the compensation committee of independent directors under the company’s 2021 Incentive Compensation Plan. Following this grant, Nolan holds 90,000 stock options directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Parker Charles Nolan
Role
Chief Financial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 90,000 | $0.00 | -- |
Holdings After Transaction:
Stock Option (right to buy) — 90,000 shares (Direct)
Footnotes (1)
- [object Object]
Key Figures
Stock options granted: 90000.0000 options
Exercise price: $0.6800 per share
Underlying shares: 90000.0000 shares
+3 more
6 metrics
Stock options granted
90000.0000 options
Grant to CFO Parker Charles Nolan on 2026-07-09
Exercise price
$0.6800 per share
Exercise price for the 90,000 stock options
Underlying shares
90000.0000 shares
Common stock underlying the stock option award
Vesting date
2027-07-09
Options vest 100% on the first anniversary of grant
Expiration date
2036-07-09
Expiration date of the stock option award
Options held after transaction
90000.0000 options
Total stock options held directly by CFO after grant
Key Terms
Stock Option (right to buy), exercise price, Incentive Compensation Plan, vest 100%
4 terms
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"
exercise price financial
"conversion_or_exercise_price: 0.6800"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
Incentive Compensation Plan financial
"under the Issuer's 2021 Incentive Compensation Plan"
An incentive compensation plan is a formal program that rewards employees and executives with bonuses, stock, or other payments tied to specific performance goals—such as revenue, profit, productivity, or long‑term share price. Investors watch these plans because they shape how leaders make decisions and take risks; like paying a coach by wins rather than effort, well‑designed plans can drive sustainable growth while poor designs can encourage short‑term behaviors that harm shareholder value.
vest 100% financial
"The stock options under this award will vest 100% on the first anniversary"
FAQ
What insider transaction did Traws Pharma (TRAW) report for CFO Parker Charles Nolan?
Traws Pharma reported that CFO Parker Charles Nolan received a grant of 90,000 stock options to buy common stock. The options were awarded as part of his compensation under the 2021 Incentive Compensation Plan and are held directly.
How many stock options were granted to the TRAW CFO and at what exercise price?
The CFO received 90,000 stock options with an exercise price of $0.68 per share. These options give him the right to purchase Traws Pharma common stock at that fixed price once vested.
When do the TRAW CFO’s newly granted stock options vest?
The stock options granted to the CFO vest 100% on the first anniversary of the July 9, 2026 grant date. This means the entire 90,000-option award becomes exercisable on July 9, 2027.
What is the expiration date of the TRAW CFO’s 90,000 stock options?
The CFO’s 90,000 stock options expire on July 9, 2036. After that date, any unexercised options become worthless and can no longer be used to purchase Traws Pharma common stock.
Under which plan were the TRAW CFO’s stock options granted?
The options were awarded under Traws Pharma’s 2021 Incentive Compensation Plan, as amended and/or restated. The grant was approved by the company’s compensation committee of independent directors overseeing executive compensation.
How many stock options does the TRAW CFO hold after this grant?
Following this grant, the CFO holds 90,000 stock options directly. This total reflects the newly awarded options reported, giving him future rights to acquire Traws Pharma common stock upon vesting and exercise.